Dose-response relationships of inhaled insulin delivered via the Aerodose insulin inhaler and subcutaneously injected insulin in patients with type 2 diabetes

Diabetes Care

Volumn 26, Issue 10, 2003, Pages 2842-2847

  Kim, Dennis ^a,b   Mudaliar, Sunder ^a,b   Chinnapongse, Sithipol ^a,b   Chu, Neelima ^a,b   Boies, Sarah M ^a   Davis, Trent ^a   Perera, Ayesh D ^c   Fishman, Robert S ^c   Shapiro, David A ^c   Henry, Robert ^a,b  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Aerogen Incorporated   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; ISOPHANE INSULIN;

ADULT; AEROSOL; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG POTENCY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INHALER; INSULIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SMOKING;

ADMINISTRATION, INHALATION; ADULT; AGED; AGED, 80 AND OVER; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; MALE; METERED DOSE INHALERS; MIDDLE AGED; TREATMENT OUTCOME;

EID: 10744228212     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.10.2842     Document Type: Article

References (17)

1. Skyler JS, Cefalu WT, Kourides IA, Landschulz WH, Balagtas CC, Cheng S, Gelfand RA: Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet 357:331-335, 2001
2. Brunner GA, Balent B, Ellmerer M, Schaupp L, Siebenhofer A, Jendle JH, Okikawa J, Pieber TR: Dose-response relation of liquid aerosol inhaled insulin in type 1 diabetic patients. Diabetologia 44: 305-308, 2001
3. Steiner S, Pfutzner A, Wilson AR, Harzar O, Heinemann L, Rave K: Technosphere/ insulin-proof of concept study with a new insulin formulation for pulmonary delivery. Exp Clin Endocrinol Diabetes 110:17-21, 2002
4. Fishman RS, Guinta D, Chambers F, Quintana R, Shapiro DA: Insulin administration via the Aerodose inhaler: comparison to subcutaneously injected insulin (Abstract). Diabetes 49 (Suppl. 1):A9, 2000
5. Kapitza C, Heise T, Heinemann L, Shapiro DA, Gopalakrishnan V, Fishman RS: Impact of particle size and aerosolization time on the metabolic effect of an inhaled insulin aerosol (Abstract). Diabetes 50 (Suppl. 2):A118, 2001
6. Perera AD, Kapitza C, Nosek L, Fishman RS, Shapiro DA, Heise T, Heinemann L: Absorption and metabolic effect of inhaled insulin: intrapatient variability after inhalation via the Aerodose inhaler in patients with type 2 diabetes. Diabetes Care 25:2276-2281, 2002
7. Dolovich MA: Influence of inspiratory flow rate, particle size, and airway caliber on aerosolized drug delivery to the lung. Res Care 45:597-608, 2000
8. Heinemann L, Traut T, Heise T: Time-action profile of inhaled insulin. Diabet Med 14:63-72, 1997
9. Heinemann L, Klappoth W, Rave K, Hompesch B, Linkeschowa R, Heise T: Intra-individual variability of the metabolic effect of inhaled insulin together with an absorption enhancer. Diabetes Care 23: 1343-1347, 2000
10. Kolterman OG, Gray RS, Griffin J, Burstein P, Insel J, Scarlett JA, Olefsky JM: Receptor and post receptor defects contribute to the insulin resistance in noninsulin-dependent diabetes mellitus. J Clin Inves 68:957-969, 1981
11. Olefsky JM, Kolterman OG: Mechanisms of insulin resistance in obesity and noninsulin-dependent (type II) diabetes. Am J Med 70:151-168, 1981
12. McElduff A, Farr S, Ward E, Okumu F, Mather L, Gonda I, Rubsamen R, Dimarchi R, Wolff R: Comparison of the pharmacokinetics and pharmacodynamics of subcutaneous and inhaled insulin lispro in healthy fasting volunteers (Abstract). Diabetes 47 (Suppl. 1):A105, 1998
13. Farr S, McElduff A, Mather LE, Okikawa J, Ward ME, Gonda I, Licko V, Rubsamen RM: Pulmonary insulin administration using the AERx system: physiological and physiochemical factors influencing insulin effectiveness in healthy fasting subjects. Diabetes Technol Ther 2:185-197, 2000
14. Rave KM, Heise T, Pfützner A, Steiner S, Heinemann L: Results of a dose-response study with a new pulmonary insulin formulation and inhaler (Abstract). Diabetes 49 (Suppl. 1):A75, 2000
15. Steiner S, Rave K, Heise T, Harzer O, Flacke F, Pfützner A, Heinemann L: Bioavailability and pharmacokinetic properties of inhaled dry powder technosphere/ insulin (Abstract). Diabetes 49 (Suppl. 1): A126, 2000
16. Laube BL, Benedict GW, Dobs AS: Time to peak insulin level, relative bioavailability and effect of site of deposition of nebulized insulin in patients with non-insulin dependent diabetes mellitus. J Aerosol Med 11:153-173, 1998
17. Patton JS, Bukar J, Nagarajan S: Inhaled insulin. Adv Drug Delivery Rev 35:235-247, 1999